Join our community of smart investors

Organic and acquisitive growth – BTG ticks all the boxes

The specialist pharmaceutical company has updated first-half expectations and announced another US acquisition
October 12, 2017

BTG (BTG) has reiterated its double-digit growth guidance for product sales in the first half of the year as demand for its speciality pharma products continues to strengthen. The specialist pharmaceutical group has upgraded expectations slightly thanks to strong royalty revenues from cancer drug Lemtrada, while broker Numis thinks high demand for Zytiga could see it beat full-year forecasts. 

IC TIP: Buy at 704p

But for long-term potential all eyes are on the interventional medicine division, where the group develops its own novel products in areas of severe medical need. Here, BTG recently began in-patient trials into its microscope beads for treating liver cancer, which have enormous sales potential. The group is also set to acquire interventional medicine group Roxwood Medical for $80m (£61m), which should help enhance its reach in the US.